Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress

Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more focused and consistent operating model. The Company also raised its full-year 2026 guidance for both net sales and adjusted EBITDA. All pro forma measures contained within this release exclude the impact of the discontinued M6™ product lines. Highlights Second quarter 2026 reported net sales of $210.9 million, representing an increase of 4% on a reported basis and 5% on a pro forma constant currency basis compared to second quarter 2025.Generated double-digit constant currency growth in Global Spine Fixation1 and Global Limb Reconstruction, reflecting strong international performance and continued demand across key growth platforms.Therapeutic Solutions (formerly Bone Growth Therapies) delivered 3% year-over-year net sales growth despite a temporary Medicare reimbursement headwind affecting bone growth stimulators during part of the second quarter.Biologics stabilized and began to regain momentum, supported by focused commercial execution.Second quarter 2026 reported net loss of $(15.8) million and non-GAAP adjusted EBITDA of $20.1 million. “Our second quarter results provide further evidence that the operational actions we have taken over the past year are beginning to show up more clearly in the business,” said Massimo Calafiore, President and Chief Executive Officer of Orthofix. “We delivered 5% pro forma, constant-currency net sales growth, supported by double-digit growth in Global Limb Reconstruction and Spine Fixation, sequential momentum in Biologics, and the restoration of Medicare reimbursement for bone growth stimulators, which removes a meaningful headwind for our Therapeutic Solutions business as we enter the second half of the year.” Mr. Calafiore continued, “While our transformation remains a work in progress, we believe Orthofix is operating from a stronger position than it was a year ago. Our focus remains on improving the quality of growth, strengthening commercial productivity, and building a more consistent path to profitability and cash generation. As we continue to execute with discipline, we believe we are building a stronger foundation for durable, profitable growth and long-term shareholder value.” 1 Spine Fixation is comprised of the Company’s Spinal Implants product category, excluding motion preservation product offerings. Financial Results Overview Second Quarter 2026 Net Sales and Financial Results The following table provides net sales by major product category and by reporting segment on a pro forma basis, removing the effects of the Company’s discontinued M6 product lines: Three Months Ended June 30, (Unaudited, U.S. Dollars, in millions) 2026 2025 Change Constant Currency Change Therapeutic Solutions $ 64.2 $ 62.6 2.5 % 2.5 % Spinal Implants, Biologics and Enabling Technologies* 109.0 104.8 4.0 % 4.0 % Global Spine* 173.2 167.4 3.5 % 3.5 % Global Limb Reconstruction 37.7 33.3 13.2 % 11.0 % Pro forma net sales* 210.9 200.7 5.1 % 4.7 % Impact from discontinuation of M6 product lines 0.0 2.4 (97.4 %) (97.5 %) Reported net sales $ 210.9 $ 203.1 3.8 % 3.5 % * Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company’s pro forma net sales to its reported figures under U.S. GAAP. The Company’s reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines. For the second quarter of 2026, net sales were $210.9 million, representing an increase of 3.8% on a reported basis and 4.7% on a non-GAAP pro forma constant currency basis compared to second quarter 2025. For the second quarter of 2026, GAAP gross margins were 71.0% and were 71.7% on a non-GAAP adjusted basis. For the second quarter of 2026, reported net loss was $(15.8) million, or $(0.39) per share compared to reported net loss of $(14.1) million, or $(0.36) per share in the prior year period. Non-GAAP adjusted EBITDA was $20.1 million, or 9.6% of pro forma net sales, in the second quarter of 2026, compared to non-GAAP adjusted EBITDA of $20.6 million, or 10.3% of pro forma net sales, in the second quarter of 2025. Liquidity Cash, cash equivalents, and restricted cash on June 30, 2026, totaled $104.4 million compared to $120.9 million on March 31, 2026. The decrease was due to arbitration award and settlement payments related to pending claims from three former executives terminated in 2023. Business Outlook Following the restoration of Medicare reimbursement for non-invasive bone growth stimulators to its prior level, second-quarter performance, and the Company’s current expectations for the remainder of the year, Orthofix is increasing its full-year 2026 guidance for both net sales and adjusted EBITDA. All measures are provided on a non-GAAP pro forma basis and are based on current foreign currency exchange rates. Net sales are now expected to range from $845 million to $855 million, an increase of $7 million at both the low and high ends of the range from the Company’s previous guidance of $838 million to $848 million issued on May 21, 2026. The updated range represents approximately 5% year-over-year pro forma constant currency growth at the midpoint and does not take into account any additional exchange rate changes that may occur this year.The Company is increasing its full-year 2026 non-GAAP adjusted EBITDA guidance to $95 million to $98 million, compared to its previous guidance of $90 million to $93 million issued on May 21, 2026. The updated range reflects continued operating discipline and cost management, while also balancing planned growth investments and geographic mix dynamics. At the midpoint, this represents 80 basis points of non-GAAP adjusted EBITDA margin expansion compared to 2025. An investor presentation for the Company’s second quarter 2026 financial results is available in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.orthofix.com. Conference Call Orthofix will host a conference call today at 8:30 AM Eastern Time to discuss the Company’s financial results for the second quarter ended June 30, 2026. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 8700861. A webcast and replay of the conference call may be accessed in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix regularly shares important updates in the “Investors” section of its website at www.orthofix.com. The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix. About Orthofix Orthofix is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company offers a differentiated portfolio of spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH™ Navigation System. Orthofix’s technology-enabled solutions are designed to support surgeons across the continuum of care and improve outcomes for patients. Learn more at Orthofix.com and follow Orthofix on LinkedIn. Forward-Looking Statements This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “positioned,” “deliver,” or “continue” or other comparable terminology. Forward-looking statements in this communication include the Company’s expectations regarding net sales and adjusted EBITDA for the year ended December 31, 2026. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, and in Part II, Item 1A under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to successfully optimize our commercial channels, (vii) our success in defending legal proceedings brought against us, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. The Company undertakes no obligation to update, and expressly disclaims any duty to update, its forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law. The Company is unable to provide expectations of GAAP net income (loss), the closest comparable GAAP measures to adjusted EBITDA (which is a non-GAAP measure), on a forward-looking basis because the Company is unable to predict, without unreasonable efforts, the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating adjusted EBITDA, which items are further described in the reconciliation tables and related descriptions below. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP. ORTHOFIX MEDICAL INC. Condensed Consolidated Statements of Operations Three Months Ended Six Months Ended June 30, June 30, (Unaudited, U.S. Dollars, in thousands, except share and per share data) 2026 2025 2026 2025 Net sales $ 210,933 $ 203,121 $ 407,641 $ 396,767 Cost of sales 61,226 63,588 118,388 135,615 Gross profit 149,707 139,533 289,253 261,152 Sales, general, and administrative 138,030 136,493 272,941 269,474 Research and development 15,944 15,934 31,264 35,700 Acquisition-related amortization, impairment, and remeasurement 3,867 3,109 7,618 20,854 Operating loss (8,134 ) (16,003 ) (22,570 ) (64,876 ) Interest expense, net (6,085 ) (3,950 ) (11,749 ) (8,456 ) Other income (expense), net (778 ) 5,730 (1,512 ) 6,976 Loss before income taxes (14,997 ) (14,223 ) (35,831 ) (66,356 ) Income tax (expense) benefit (801 ) 142 (875 ) (819 ) Net loss $ (15,798 ) $ (14,081 ) $ (36,706 ) $ (67,175 ) Net loss per common share: Basic $ (0.39 ) $ (0.36 ) $ (0.90 ) $ (1.71 ) Diluted (0.39 ) (0.36 ) (0.90 ) (1.71 ) Weighted average number of common shares (in millions): Basic 40.9 39.5 40.7 39.3 Diluted 40.9 39.5 40.7 39.3 ORTHOFIX MEDICAL INC. Condensed Consolidated Balance Sheets (U.S. Dollars, in thousands, except par value data) June 30, 2026 December 31, 2025 (Unaudited) Assets Current assets Cash and cash equivalents $ 103,810 $ 82,025 Restricted Cash 595 3,090 Accounts receivable, net of allowances of $10,563 and $8,308, respectively 135,818 135,746 Inventories 184,475 172,319 Prepaid expenses and other current assets 21,434 23,667 Total current assets 446,132 416,847 Property, plant, and equipment, net 130,757 129,399 Intangible assets, net 65,972 72,765 Goodwill 194,934 194,934 Other long-term assets 35,225 36,702 Total assets $ 873,020 $ 850,647 Liabilities and shareholders’ equity Current liabilities Accounts payable $ 63,531 $ 58,392 Current portion of finance lease liability 125 837 Other current liabilities 93,354 111,253 Total current liabilities 157,010 170,482 Long-term debt 221,591 157,391 Long-term portion of finance lease liability 12,903 17,060 Other long-term liabilities 52,336 55,677 Total liabilities 443,840 400,610 Contingencies Shareholders’ equity Common shares $0.10 par value; 100,000 shares authorized; 40,730 and 39,834 issued and outstanding as of June 30, 2026, and December 31, 2025, respectively 4,073 3,983 Additional paid-in capital 830,423 813,769 Accumulated deficit (405,039 ) (368,333 ) Accumulated other comprehensive income (loss) (277 ) 618 Total shareholders’ equity 429,180 450,037 Total liabilities and shareholders’ equity $ 873,020 $ 850,647 ORTHOFIX MEDICAL INC. Non-GAAP Financial Measures The following tables present reconciliations of various financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to various non-GAAP financial measures that exclude (or in the case of free cash flow, include) items specified in the tables. The GAAP measures shown in the tables below represent the most comparable GAAP measure to the applicable non-GAAP measure(s) shown in the table. For further information regarding the nature of these exclusions, why the Company believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s current report on Form 8-K regarding this press release filed today with the SEC available on the SEC’s website at www.sec.gov and on the “Investors” page of the Company’s website at www.orthofix.com. The Company’s non-GAAP financial measures for the three and six months ended June 30, 2026, and 2025, have been adjusted to eliminate the financial effects of the Company’s decision to discontinue its M6 product lines. Adjusted Gross Profit and Adjusted Gross Margin Three Months Ended June 30, Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Gross profit $ 149,707 $ 139,533 $ 289,253 $ 261,152 Share-based compensation and long-term incentive plan expense 462 467 793 929 SeaSpine merger-related costs 225 4,341 (303 ) 4,941 Restructuring costs and impairments related to M6 product lines 217 2,791 (220 ) 13,710 Gross profit attributable to M6 product line operations (53 ) (1,639 ) (295 ) (2,545 ) Strategic investments — 43 — 56 Amortization/depreciation of acquired long-lived assets 108 351 285 664 Employee transition costs 593 — 593 — Adjusted gross profit $ 151,259 $ 145,887 $ 290,106 $ 278,907 Adjusted gross margin as a percentage of reported net sales 71.7 % 71.8 % 71.2 % 70.3 % Adjusted gross margin as a percentage of pro forma net sales 71.7 % 72.7 % 71.2 % 71.5 % Adjusted EBITDA Three Months Ended June 30, Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Net loss $ (15,798 ) $ (14,081 ) $ (36,706 ) $ (67,175 ) Income tax expense (benefit) 801 (141 ) 875 819 Interest expense, net 6,085 3,950 11,749 8,456 Depreciation and amortization 13,273 16,871 26,766 51,302 Share-based compensation and long-term incentive plan expense 7,945 7,824 14,583 14,293 Foreign exchange impact 746 (2,751 ) 1,646 (3,795 ) SeaSpine merger-related costs 572 4,886 503 6,017 Restructuring costs and impairments related to M6 product lines 217 3,651 (220 ) 13,531 Operating losses attributable to M6 product lines 868 (297 ) 1,558 1,949 Strategic investments 634 353 1,584 3,867 Acquisition-related fair value adjustments 868 (763 ) 1,618 (1,373 ) Interest and loss on investments — (31 ) (16 ) (31 ) Litigation and investigation costs 2,185 4,029 5,101 7,071 Employee retention credit — (2,854 ) (951 ) (2,854 ) Employee transition costs 1,742 — 1,742 — Adjusted EBITDA $ 20,138 $ 20,646 $ 29,832 $ 32,077 Adjusted EBITDA as a percentage of reported net sales 9.5 % 10.2 % 7.3 % 8.1 % Adjusted EBITDA as a percentage of pro forma net sales 9.6 % 10.3 % 7.3 % 8.2 % Adjusted Net Income (Loss) Three Months Ended June 30, Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Net loss $ (15,798 ) $ (14,081 ) $ (36,706 ) $ (67,175 ) Share-based compensation and long-term incentive plan expense 7,945 7,824 14,583 14,293 Foreign exchange impact 746 (2,751 ) 1,646 (3,795 ) SeaSpine merger-related costs 574 7,786 591 9,260 Restructuring costs and impairments related to M6 product lines 176 4,257 (448 ) 34,461 Operating losses attributable to M6 product lines 1,006 (766 ) 1,922 1,922 Strategic investments 637 364 1,590 3,907 Acquisition-related fair value adjustments 868 (761 ) 1,618 (1,371 ) Amortization/depreciation of acquired long-lived assets 3,107 4,221 6,285 8,853 Litigation and investigation costs 2,185 4,029 5,101 7,071 Interest and loss on investments — (31 ) (16 ) (31 ) Employee retention credit — (3,616 ) (1,135 ) (3,616 ) Employee transition costs 1,742 — 1,742 — Long-term income tax rate adjustment (316 ) (1,915 ) 1,534 (468 ) Adjusted net income (loss) $ 2,872 $ 4,560 $ (1,693 ) $ 3,311 Cash Flow and Free Cash Flow Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 Net cash used in operating activities $ (23,834 ) $ (6,752 ) Net cash used in investing activities (23,162 ) (13,833 ) Net cash provided by financing activities 66,421 1,989 Effect of exchange rate changes on cash (135 ) 1,547 Net change in cash and cash equivalents $ 19,290 $ (17,049 ) Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 Net cash used in operating activities $ (23,834 ) $ (6,752 ) Capital expenditures (23,308 ) (13,845 ) Free cash flow $ (47,142 ) $ (20,597 ) Reconciliation of Non-GAAP Financial Measures to Reported Operating Expenses Three Months Ended June 30, Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Sales, general, and administrative $ 138,030 $ 136,493 $ 272,941 $ 269,474 Reconciling items impacting sales, general, and administrative: SeaSpine merger-related costs (270 ) (3,384 ) (756 ) (4,142 ) Restructuring costs and impairments related to M6 product lines 41 (1,393 ) 228 (4,729 ) Sales, general, and administrative expense attributable to M6 product lines (636 ) (243 ) (1,685 ) (2,631 ) Strategic investments (633 ) (194 ) (1,581 ) (1,741 ) Amortization/depreciation of acquired long-lived assets — — — (60 ) Litigation and investigation costs (2,185 ) (3,579 ) (5,101 ) (6,621 ) Employee transition costs (1,148 ) — (1,148 ) — Sales, general, and administrative expense, as adjusted $ 133,199 $ 127,700 $ 262,898 $ 249,550 As a percentage of reported net sales 63.1 % 62.9 % 64.5 % 62.9 % As a percentage of pro forma net sales 63.2 % 63.6 % 64.5 % 64.0 % Three Months Ended June 30, Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Research and development expense, as reported $ 15,944 $ 15,934 $ 31,264 $ 35,700 Reconciling items impacting research and development: SeaSpine merger-related costs (80 ) (62 ) (139 ) (178 ) Restructuring costs and impairments related to M6 product lines — (77 ) — (1,929 ) Research and development expense attributable to M6 product lines (413 ) (602 ) (659 ) (1,794 ) Strategic investments (3 ) (127 ) (8 ) (2,110 ) Litigation and investigation costs — (450 ) — (450 ) Research and development expense, as adjusted $ 15,448 $ 14,616 $ 30,458 $ 29,239 As a percentage of reported net sales 7.3 % 7.2 % 7.5 % 7.4 % As a percentage of pro forma net sales 7.3 % 7.3 % 7.5 % 7.5 % Reconciliations of Non-GAAP Financial Measures to Reported Non-Operating (Income) Expense Three Months Ended June 30, Six Months Ended June 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Non-operating (income) expense $ 6,863 $ (1,780 ) $ 13,261 $ 1,480 Reconciling items impacting non-operating expense: Restructuring costs and impairments related to M6 product lines — 3 — 3 Losses (income) attributable to M6 product lines (12 ) (26 ) 126 (41 ) Foreign exchange impact (746 ) 2,751 (1,646 ) 3,795 Interest and loss on investments — 31 16 31 Employee retention credit — 3,617 1,135 3,617 Non-operating expense, as adjusted $ 6,105 $ 4,596 $ 12,892 $ 8,885 As a percentage of reported net sales 2.9 % 2.3 % 3.2 % 2.2 % As a percentage of pro forma net sales 2.9 % 2.3 % 3.2 % 2.3 % Company Contact Investors and Media Julie Dewey, IRC Chief Investor Relations & Communications Officer [email protected] +1 209.613.6945 Source: Orthofix Medical Inc.